文献速递慢性肾脏病遗传性与小管间质肾病

托伐普坦相关肝损伤在常染色体显性多囊肾病试验参与者中的临床模式:关键临床试验分析

Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials.
PubMed 文献 · Am J Kidney Dis · 2022-09-30

该分析基于托伐普坦治疗常染色体显性多囊肾病的前瞻性临床试验安全性数据,纳入超过2900例用药者。REPRISE中托伐普坦组丙氨酸氨基转移酶升至正常上限3倍以上者38/681(5.6%),安慰剂组8/685(1.2%);未观察到符合Hy法则的实验室病例。肝酶升高多发生于用药18个月内,停药或中断后恢复。

要点

  • REPRISE中丙氨酸氨基转移酶升至正常上限3倍以上者托伐普坦组5.6%,安慰剂组1.2%。
  • REPRISE及长期扩展试验均未出现Hy法则实验室标准病例。
  • 肝酶升高多发生于托伐普坦起始后18个月内,此后较少见。

核心结论

  • REPRISE和长期扩展试验中未出现Hy法则病例,支持在托伐普坦暴露前18个月每月监测肝酶、之后每3个月监测,以及时发现和管理肝酶升高,与药品说明书推荐一致。

研究设计与样本

  • 对托伐普坦治疗常染色体显性多囊肾病的前瞻性临床试验安全性数据进行分析。
  • 多中心临床试验,纳入超过2900例托伐普坦治疗参与者,其中超过2300例至少暴露18个月。
  • 托伐普坦以分次剂量方案每日两次给药。
  • 结局为定期实验室监测发现的肝酶水平升高频率。

主要发现

  • REPRISE试验中,托伐普坦组38/681(5.6%)对比安慰剂组8/685(1.2%)出现丙氨酸氨基转移酶升至正常上限3倍以上。
  • TEMPO 3:4中,托伐普坦组40/957(4.4%)对比安慰剂组5/484(1.0%)出现丙氨酸氨基转移酶升至正常上限3倍以上。
  • REPRISE或长期扩展试验中无参与者出现丙氨酸氨基转移酶升至正常上限3倍以上同时总胆红素升至正常上限2倍以上(Hy法则实验室标准)。
  • 基于扩展数据集,肝酶升高最常发生于托伐普坦起始后18个月内,此后较少见;治疗中断或停药后升高水平恢复至正常或接近正常。
  • 38例患者在初始药物性肝损伤事件后再次接受托伐普坦,其中30例肝酶升高再现;另1例参与者在初始事件后表现为临床「适应」,尽管继续使用托伐普坦但肝酶升高消退。

关键数值与推荐

  • REPRISE:丙氨酸氨基转移酶升至正常上限3倍以上,托伐普坦组38/681(5.6%)对比安慰剂组8/685(1.2%)。
  • TEMPO 3:4:丙氨酸氨基转移酶升至正常上限3倍以上,托伐普坦组40/957(4.4%)对比安慰剂组5/484(1.0%)。
  • Hy法则实验室标准定义为丙氨酸氨基转移酶升至正常上限3倍以上同时总胆红素升至正常上限2倍以上,REPRISE和长期扩展试验中无此类病例。

临床怎么用

  • 原文结论支持在托伐普坦暴露前18个月每月监测肝酶、之后每3个月监测,以及时发现和管理肝酶升高,该做法与药品说明书推荐一致。

局限性

  • 回顾性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Tolvaptan is associated with risk of drug-induced liver injury when used to treat autosomal dominant polycystic kidney disease (ADPKD). After this risk was described based on the clinical trials TEMPO 3:4 and TEMPO 4:4, additional data from the REPRISE trial and a long-term extension of TEMPO 4:4, REPRISE, and other tolvaptan trials in ADPKD have become available. To further characterize the hepatic safety profile of tolvaptan, an analysis of the expanded dataset was conducted. STUDY DESIGN: Analysis of safety data from prospective clinical trials of tolvaptan. SETTING & PARTICIPANTS: Multicenter clinical trials including more than 2,900 tolvaptan-treated participants, more than 2,300 with at least 18 months of drug exposure. INTERVENTION: Tolvaptan administered twice daily in split-dose regimens. OUTCOMES: Frequency of liver enzyme level increases detected by regular laboratory monitoring. RESULTS: In the placebo-controlled REPRISE trial, more tolvaptan- than placebo-treated participants (38 of 681 [5.6%] vs 8 of 685 [1.2%]) experienced alanine aminotransferase level increases to >3× the upper limit of normal (ULN), similar to TEMPO 3:4 (40 of 957 [4.4%] vs 5 of 484 [1.0%]). No participant in REPRISE or the long-term extension experienced concurrent alanine aminotransferase level increases to >3× ULN and total bilirubin increases to >2× ULN ("Hy's Law" laboratory criteria). Based on the expanded dataset, liver enzyme increases most often occurred within 18 months after tolvaptan initiation and were less frequent thereafter. Increased levels returned to normal or near normal after treatment interruption or discontinuation. Thirty-eight patients were rechallenged with tolvaptan after the initial drug-induced liver injury episode, with return of liver enzyme level increases in 30; 1 additional participant showed a clinical "adaptation" after the initial episode, with resolution of the enzyme level increases despite continuation of tolvaptan. LIMITATIONS: Retrospective analysis. CONCLUSIONS: The absence of Hy's Law cases in REPRISE and the long-term extension trial support monthly liver enzyme monitoring during the first 18 months of tolvaptan exposure and every 3 months thereafter to detect and manage enzyme level increases, as is recommended on the drug label. FUNDING: Otsuka Pharmaceutical Development & Commercialization, Inc. TRIAL REGISTRATION: Trials included in the dataset were registered at ClinicalTrials.gov with study numbers NCT00428948 (TEMPO 3:4), NCT01214421 (TEMPO 4:4), NCT02160145 (REPRISE), and NCT02251275 (long-term extension).

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Alpers DH, Lewis JH, Hunt CM, et al. Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials. Am J Kidney Dis. 2022. PMID: 36191725. doi:10.1053/j.ajkd.2022.08.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。